237 related articles for article (PubMed ID: 21656387)
21. Complete response to chemotherapy in primary hepatic lymphoma.
Zafar MS; Aggarwal S; Bhalla S
J Cancer Res Ther; 2012; 8(1):114-6. PubMed ID: 22531527
[TBL] [Abstract][Full Text] [Related]
22. Long term results of a phase 2 study of vincristine sulfate liposome injection (Marqibo(®) ) substituted for non-liposomal vincristine in cyclophosphamide, doxorubicin, vincristine, prednisone with or without rituximab for patients with untreated aggressive non-Hodgkin lymphomas.
Hagemeister F; Rodriguez MA; Deitcher SR; Younes A; Fayad L; Goy A; Dang NH; Forman A; McLaughlin P; Medeiros LJ; Pro B; Romaguera J; Samaniego F; Silverman JA; Sarris A; Cabanillas F
Br J Haematol; 2013 Sep; 162(5):631-8. PubMed ID: 23802738
[TBL] [Abstract][Full Text] [Related]
23. [Diffuse large B-cell lymphoma following nodular lymphocyte predominant Hodgkin's lymphoma: report of a case].
Chen DB; Wang Y; Shen DH
Zhonghua Bing Li Xue Za Zhi; 2010 Sep; 39(9):635-6. PubMed ID: 21092597
[No Abstract] [Full Text] [Related]
24. Central nervous system (CNS) relapse in diffuse large B cell lymphoma (DLBCL): pre- and post-rituximab.
Tai WM; Chung J; Tang PL; Koo YX; Hou X; Tay KW; Quek R; Tao M; Lim ST
Ann Hematol; 2011 Jul; 90(7):809-18. PubMed ID: 21229246
[TBL] [Abstract][Full Text] [Related]
25. [A case of gastric stenosis due to primary gastric malignant lymphoma during administration of R-CHOP].
Tamai Y; Murakami E; Nakamori Y; Mizutani M; Sekine T
Gan To Kagaku Ryoho; 2011 Aug; 38(8):1371-3. PubMed ID: 21829084
[TBL] [Abstract][Full Text] [Related]
26. [Primary bone lymphoma with multicentric involvement].
Graziadio M; Medina N; Amato M; Ardaiz Mdel C; Ilutovich S; Torino M
Medicina (B Aires); 2012; 72(5):428-30. PubMed ID: 23089121
[TBL] [Abstract][Full Text] [Related]
27. Peripheral blood lymphocyte/monocyte ratio predicts outcome in follicular lymphoma and in diffuse large B-cell lymphoma patients in the rituximab era.
Belotti A; Doni E; Bolis S; Rossini F; Casaroli I; Pezzatti S; Pogliani EM; Pioltelli PE
Clin Lymphoma Myeloma Leuk; 2015 Apr; 15(4):208-13. PubMed ID: 25468321
[TBL] [Abstract][Full Text] [Related]
28. Primary non-Hodgkin's lymphoma of the mandible. Report of a case.
Longo F; De Maria G; Esposito P; Califano L
Int J Oral Maxillofac Surg; 2004 Dec; 33(8):801-3. PubMed ID: 15556331
[TBL] [Abstract][Full Text] [Related]
29. Clinicopathologic features of the nine patients with primary diffuse large B cell lymphoma of the breast.
Seker M; Bilici A; Ustaalioglu BO; Yilmaz B; Ozturk B; Ünal A; Dane F; Ozdemir NY; Elkiran ET; Kalender ME; Gumus M; Benekli M
Arch Gynecol Obstet; 2011 Aug; 284(2):405-9. PubMed ID: 20872226
[TBL] [Abstract][Full Text] [Related]
30. Treatment of a patient with adnexal lymphoma with Rituximab.
Bilgir O; Bilgir F; Calan M; Yuksel A; Sari F; Oztekin O
Transfus Apher Sci; 2011 Apr; 44(2):135-7. PubMed ID: 21320802
[TBL] [Abstract][Full Text] [Related]
31. HIV status does not impair the outcome of patients diagnosed with diffuse large B-cell lymphoma treated with R-CHOP in the cART era.
Coutinho R; Pria AD; Gandhi S; Bailey K; Fields P; Cwynarski K; Wilson A; Papanastasopoulos P; Tenant-Flowers M; Webb A; Burns F; Marcus RE; Orkin C; Montoto S; Bower M
AIDS; 2014 Mar; 28(5):689-97. PubMed ID: 24418826
[TBL] [Abstract][Full Text] [Related]
32. Primary anaplastic large B-cell lymphoma in mandible: Long-term complete remission with R-CHOP regimen and involved field radiotherapy.
Niscola P; Palombi M; Trawinska MM; Scaramucci L; Giovannini M; Perrotti AP; Fabritiis Pd; Fratoni S
Oral Oncol; 2009 Sep; 45(9):e113. PubMed ID: 19457710
[No Abstract] [Full Text] [Related]
33. A study on nm23-H1 expression in diffuse large B-cell lymphoma that was treated with CyclOBEAP plus rituximab therapy.
Niitsu N; Tamaru J; Yoshino T; Nakamura N; Nakamura S; Ohshima K; Nakamine H; Okamoto M
Ann Hematol; 2011 Feb; 90(2):185-92. PubMed ID: 20809421
[TBL] [Abstract][Full Text] [Related]
34. Serum interleukin-18 level is associated with the outcome of patients with diffuse large B-cell lymphoma treated with CHOP or R-CHOP regimens.
Goto N; Tsurumi H; Kasahara S; Kanemura N; Hara T; Yasuda I; Shimizu M; Murakami N; Sawada M; Yamada T; Takemura M; Seishima M; Kito Y; Takami T; Moriwaki H
Eur J Haematol; 2011 Sep; 87(3):217-27. PubMed ID: 21575062
[TBL] [Abstract][Full Text] [Related]
35. Immunohistochemical double-hit score is a strong predictor of outcome in patients with diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone.
Green TM; Young KH; Visco C; Xu-Monette ZY; Orazi A; Go RS; Nielsen O; Gadeberg OV; Mourits-Andersen T; Frederiksen M; Pedersen LM; Møller MB
J Clin Oncol; 2012 Oct; 30(28):3460-7. PubMed ID: 22665537
[TBL] [Abstract][Full Text] [Related]
36. Treatment of gastrointestinal diffuse large B cell lymphoma in China: a 10-year retrospective study of 114 cases.
Li X; Shen W; Cao J; Wang J; Chen F; Wang C; Zou S; Shen B; Zhao R; Li J; Shen Z
Ann Hematol; 2012 Nov; 91(11):1721-9. PubMed ID: 22733613
[TBL] [Abstract][Full Text] [Related]
37. The isolated extranodal relapse of the isolated extranodal non- Hodgkin lymphoma: A case report.
Comez G; Goktepe MF; Oztuzcu S; Sevinc A; Camci C
J Cancer Res Ther; 2015; 11(3):645. PubMed ID: 26458599
[TBL] [Abstract][Full Text] [Related]
38. Randomized phase II study of concurrent and sequential combinations of rituximab plus CHOP (cyclophosphamide, doxorubicin, vincristine and prednisolone) chemotherapy in untreated indolent B-cell non-Hodgkin lymphoma: 7-year follow-up results.
Tobinai K; Ogura M; Itoh K; Kinoshita T; Hotta T; Watanabe T; Morishima Y; Igarashi T; Terauchi T; Ohashi Y;
Cancer Sci; 2010 Dec; 101(12):2579-85. PubMed ID: 20942866
[TBL] [Abstract][Full Text] [Related]
39. Addition of rituximab to reduced-dose CHOP chemotherapy is feasible for elderly patients with diffuse large B-cell lymphoma.
Shin HJ; Chung JS; Song MK; Kim SK; Choe S; Cho GJ
Cancer Chemother Pharmacol; 2012 May; 69(5):1165-72. PubMed ID: 22215473
[TBL] [Abstract][Full Text] [Related]
40. Lack of benefit of central nervous system prophylaxis for diffuse large B-cell lymphoma in the rituximab era: findings from a large national database.
Kumar A; Vanderplas A; LaCasce AS; Rodriguez MA; Crosby AL; Lepisto E; Czuczman MS; Nademanee A; Niland J; Gordon LI; Millenson M; Zelenetz AD; Friedberg JW; Abel GA
Cancer; 2012 Jun; 118(11):2944-51. PubMed ID: 22006274
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
